Record Information |
---|
Version | 2.0 |
---|
Creation Date | 2009-07-21 20:28:10 UTC |
---|
Update Date | 2014-12-24 20:25:54 UTC |
---|
Accession Number | T3D2958 |
---|
Identification |
---|
Common Name | Bethanechol |
---|
Class | Small Molecule |
---|
Description | Bethanechol is a synthetic ester structurally and pharmacologically related to acetylcholine. A slowly hydrolyzed muscarinic agonist with no nicotinic effects, bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, cardiac rate changes, and bronchial spasms. [PubChem] |
---|
Compound Type | - Amine
- Carbamate
- Drug
- Ester
- Ether
- Metabolite
- Muscarinic Agonist
- Organic Compound
- Parasympathomimetic
- Synthetic Compound
|
---|
Chemical Structure | |
---|
Synonyms | Synonym | (2-Hydroxypropyl)trimethylammonium carbamate | 2-(Carbamoyloxy)-N,N,N-trimethylpropan-1-aminium | 2-Carbamoyloxypropyl-trimethylazanium | Amidopropyldimethylbetaine | Besacholine | beta-Methyl Carbachol Chloride | Bethaine Choline Chloride | Bethanechol Chloride | BTC | Carbamoyl-beta-methylcholine | carbamoyl-β-methylcholine | Carbamyl-beta-methylcholine | carbamyl-β-methylcholine | Carbamylmethylcholine Chloride | Duvoid | Myotonachol | Myotonine | Urabeth | Urecholine | Uro-Carb |
|
---|
Chemical Formula | C7H17N2O2 |
---|
Average Molecular Mass | 161.222 g/mol |
---|
Monoisotopic Mass | 161.128 g/mol |
---|
CAS Registry Number | 674-38-4 |
---|
IUPAC Name | 1-(trimethylazaniumyl)propan-2-yl carbamate |
---|
Traditional Name | bethanechol |
---|
SMILES | CC(C[N+](C)(C)C)OC(O)=N |
---|
InChI Identifier | InChI=1/C7H16N2O2/c1-6(11-7(8)10)5-9(2,3)4/h6H,5H2,1-4H3,(H-,8,10)/p+1 |
---|
InChI Key | InChIKey=NZUPCNDJBJXXRF-UHFFFAOYNA-O |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as tetraalkylammonium salts. These are organonitrogen compounds containing a quaternary ammonium substituted with four alkyl chains. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic nitrogen compounds |
---|
Class | Organonitrogen compounds |
---|
Sub Class | Quaternary ammonium salts |
---|
Direct Parent | Tetraalkylammonium salts |
---|
Alternative Parents | |
---|
Substituents | - Tetraalkylammonium salt
- Carboximidic acid derivative
- Organic oxygen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Organic salt
- Organooxygen compound
- Imine
- Amine
- Organic cation
- Aliphatic acyclic compound
|
---|
Molecular Framework | Aliphatic acyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Exogenous |
---|
Cellular Locations | |
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | Not Available |
---|
Pathways | Not Available |
---|
Applications | |
---|
Biological Roles | |
---|
Chemical Roles | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Appearance | White powder. |
---|
Experimental Properties | Property | Value |
---|
Melting Point | about 220°C | Boiling Point | Not Available | Solubility | 10 mg/mL (chloride salt) | LogP | Not Available |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | Deposition Date | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-05fu-9200000000-ce89fb005ab6417b9823 | 2017-08-28 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-03di-3900000000-3dba79e269dc8a5a9906 | 2017-09-01 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-0w2a-7900000000-5938fdfa6269132e896a | 2017-09-01 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-0h2g-9300000000-a630235eb0d4cfee2ba0 | 2017-09-01 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | Not Available | 2021-09-25 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | Not Available | 2021-09-25 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | Not Available | 2021-09-25 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | Not Available | 2021-09-25 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | Not Available | 2021-09-25 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | Not Available | 2021-09-25 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | Not Available | 2021-09-25 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | Not Available | 2021-09-25 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | Not Available | 2021-09-25 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | Not Available | 2021-09-25 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | Not Available | 2021-09-25 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | Not Available | 2021-09-25 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | Not Available | 2021-09-25 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | Not Available | 2021-09-25 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | Not Available | 2021-09-25 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | Not Available | 2021-09-25 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | Not Available | 2021-09-25 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | Not Available | 2021-09-25 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | Not Available | 2021-09-25 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | Not Available | 2021-09-25 | View Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | Oral |
---|
Mechanism of Toxicity | Bethanechol directly stimulates cholinergic receptors in the parasympathetic nervous system while stimulating the ganglia to a lesser extent. Its effects are predominantly muscarinic, inducing little effect on nicotinic receptors and negligible effects on the cardiovascular system. |
---|
Metabolism | Not Available |
---|
Toxicity Values | Not Available |
---|
Lethal Dose | Not Available |
---|
Carcinogenicity (IARC Classification) | No indication of carcinogenicity to humans (not listed by IARC). |
---|
Uses/Sources | For the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention. |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | Not Available |
---|
Symptoms | Not Available |
---|
Treatment | Atropine Sulfate is a specific antidote. The recommended dose for adults is 0.6 mg. Repeat doses can be given every two hours, according to clinical response. The recommended dosage in infants and children up to 12 years of age is 0.01 mg/kg (to a maximum single dose of 0.4 mg) repeated every two hours as needed until the desired effect is obtained or adverse effects of atropine preclude further usage. Subcutaneous injection of atropine is preferred except in emergencies when the intravenous route may be employed. (2) |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | DB01019 |
---|
HMDB ID | HMDB15154 |
---|
PubChem Compound ID | 2370 |
---|
ChEMBL ID | CHEMBL1482 |
---|
ChemSpider ID | 2280 |
---|
KEGG ID | C06850 |
---|
UniProt ID | Not Available |
---|
OMIM ID | |
---|
ChEBI ID | 3084 |
---|
BioCyc ID | Not Available |
---|
CTD ID | Not Available |
---|
Stitch ID | Bethanechol |
---|
PDB ID | Not Available |
---|
ACToR ID | Not Available |
---|
Wikipedia Link | Bethanechol |
---|
References |
---|
Synthesis Reference | Major, R.T. and Bonnett, H.T.; U.S. Patent 2,322,375: June 22,1943; assigned to Merck &
Co., Inc. |
---|
MSDS | Link |
---|
General References | - Drugs.com [Link]
- RxList: The Internet Drug Index (2009). [Link]
|
---|
Gene Regulation |
---|
Up-Regulated Genes | Not Available |
---|
Down-Regulated Genes | Not Available |
---|